- ►nih.gov [PDF] C Lindén, A Alm - British Journal of Ophthalmology, 2001 - bjo.bmj.com RESULTS The IOP reduction on days 2 and 3 was greater in the eyes treated with
four daily doses (p<0.01). During the following period there were no
statistically significant differences between the eyes. After 3 weeks ... Cited by 5 - Related articles - BL Direct - All 8 versions
U DARHAD, M NAKAMURA, M FUJIOKA, Y … - The Kobe journal of medical sciences, 2008 - med.kobe-u.ac.jp Kobe J. Med. Sci., Vol. 53, No. 6, pp. 297-304, 2007 ... Phone: 81-78-382-6048
FAX: 81-78-382-6059 E-mail: manakamu@med.kobe-u.ac.jp ... Intraocular Pressure
Lowering Effect of Once Daily ... URTOGTAH DARHAD, MAKOTO NAKAMURA, MIYUKI ... Related articles - View as HTML - All 3 versions
E Martin, JM Martinez-de-la-Casa, J Garcia- … - Eye, 2005 - nature.com A prospective, randomized, parallel-group trial performed on 30 eyes of 30
patients per group. The main outcome measure was the difference between the IOP
value taken between the baseline visit and the 6-month-visit. Macular ... Related articles - All 2 versions
JR Gonzalez, L Baiza-Duran, J Quintana-Hau … - The Journal of Clinical Pharmacology, 2007 - jcp.sagepub.com From the Clinical Research Department, Laboratorios Sophia, SA de CV,
Guadalajara, Mexico (Dr Gonzalez, Dr Baiza-Duran, Dr Quintana-Hau, Mr
Tornero-Montaño), Sección de Farmacología, Centro de Investigación y de ... Cited by 1 - Related articles - BL Direct - All 7 versions
[CITATION] for the bimatoprost/latanoprost study group (2003) A six-month randomized clinical trial …
K Erkilic, OF Ekinciler, GE Mirza, H Doğan, N … - International journal of clinical pharmacology research, 1996 - ncbi.nlm.nih.gov Prostaglandin F2 alpha (PGF2 alpha) as its tromethamine salt was topically
applied, and hypotensive and other ocular effects were studied, in glaucomatous
human eyes. After baseline intraocular pressure (IOP) measurements, 100 ... Cited by 2 - Related articles - BL Direct - All 3 versions
[CITATION] Incidência de edema cistóide de mácula com o uso de Xalatan® em afácicos e …
